MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - November 09, 2012) - The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present at two upcoming international investor conferences:
Deutsches Eigenkapitalforum Date: November 13, 2012, 1:30 pm CET (7:30 am EST, 12:30 pm GMT) Venue: Frankfurt, Germany Participants: Jens Holstein, CFO of MorphoSys AG Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Jefferies Global Healthcare Conference Date: November 15, 2012, 2:20 pm GMT (9:20 am EST, 3:20 pm CET) Venue: London, UK Participants: Jens Holstein, CFO of MorphoSys AG Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR American College for Rheumatology (ACR) Annual Meeting Date: November 13, 2012, 3:00 pm EST (10:00 pm GST, 9:00 pm CET) Venue: Washington, USA Prof. Harald Burkhardt, Professor of Rheumatology and Head of the Division of Rheumatology at Goethe University Frankfurt will present data from the phase 1b/2a clinical trial evaluating MorphoSys’s proprietary HuCAL antibody MOR103 in rheumatoid arthritis.
The PDF version of the presentation will be provided at www.morphosys.com. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Media Release (PDF): http://hugin.info/130295/R/1656672/535663.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1656672]
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
